Pushing opioids. Bribing doctors. Making millions. In Opioids, Inc., FRONTLINE and the Financial Times investigate how the drug company Insys Therapeutics profited from a fentanyl-based painkiller up to 100 times stronger than morphine—and how some Wall Street investors looked the other way even as questions about the company’s practices mounted.

A year in the making, Opioids, Inc. tells the inside story of how Insys profited from Subsys, a fast-acting fentanyl-based spray that’s been linked to hundreds of deaths. Tactics included targeting high-prescribing doctors and nurse practitioners known within the company as “whales,” misleading insurers, and holding contests for the sales team: the higher the prescription doses they got doctors to write, the larger the cash prize—despite the dangers to patients.